title: Reduced efficacy of multiple doses of CpG-matured dendritic cell tumor vaccine in an experimental model.
abstract: CpG motifs have been advanced as agents that stimulate the maturation of DCs for immunotherapy. The present study tested the hypothesis that multiple doses of CpG-matured DC vaccine would be efficacious for complete eradication of experimentally-induced tumor. Accordingly, WEHI164 cells were implanted subcutaneously in the flank of BALB/c mice. During DC culture, tumor lysate was added to immature DCs followed by addition of CpG or non-CpG control 4-6h later. A total of three doses of CpG or non-CpG control-matured DCs were injected around tumors. The results showed that multiple doses of CpG-matured DCs led to considerable decrease in cytotoxicity of lymphocytes and significantly increased tumor growth rate compared to a single dose. Further, mice which received three doses of the vaccine also displayed significant FoxP3 in tumor tissue. In conclusion, multiple doses of CpG-matured DCs exhibited decreased anti-tumor immunity in association with increased expression of FoxP3.
authors: Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors: Arash
authors: A
authors: Pourgholaminejad
authors: Arezoo
authors: A
authors: Jamali
authors: Morteza
authors: M
authors: Samadi-Foroushani
authors: Afshin
authors: A
authors: Amari
authors: Reza
authors: R
authors: Mirzaei
authors: Bita
authors: B
authors: Ansaripour
authors: Nemat
authors: N
authors: Khansari
authors: Mohammad Reza
authors: MR
authors: Aghasadeghi
authors: Babak
authors: B
authors: Baban
authors: Jamshid
authors: J
authors: Hadjati
mesh_terms: D000818:Animals; D001483:Base Sequence; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002454:Cell Differentiation / Q000276:immunology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers / Q000235:genetics; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D051858:Forkhead Transcription Factors / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism
chemical_list: D019496:Cancer Vaccines; C423449:CpG ODN 1826; D017931:DNA Primers; D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse; D009838:Oligodeoxyribonucleotides